HCP5 and acute myeloid leukemia: ITGAM, HSPA1B, and HCP5 were then confirmed to negatively correlate with the prognosis of AML patients using the Kaplan–Meier method (Figure 4D), and patients with high riskScore had significantly shorter overall survival than those with low riskScore and a favorite prognostic predictive value in determining the survival rates of AML patients (1-year AUC = 0.694, 3-year AUC = 0.751, and 5-year AUC = 0.772; Figure 4E (a) and (b)).